Ferritin: Optimal Levels, Iron Stores, and What High Ferritin Actually Means

Ferritin is the primary storage form of iron and the best single marker of total body iron stores. But ferritin is also an acute-phase reactant — elevated by inflammation independently of iron status. Here's how to interpret ferritin correctly and what the evidence says about optimal ranges.

Medical disclaimer: This article is for educational and research purposes only. It does not constitute medical advice. Reference ranges and clinical thresholds vary between laboratories and depend on individual clinical context. Always consult a qualified Australian healthcare practitioner before making decisions about iron supplementation, genetic testing, or treatment based on ferritin results.

Ferritin is simultaneously the most useful and the most misinterpreted marker in iron metabolism. On one hand, it is the best available single measure of total body iron stores — a window into the reserves held in hepatocytes, macrophages, and bone marrow that sustains iron supply to every cell in the body. On the other hand, ferritin is an acute-phase reactant: the liver synthesises more of it in response to inflammatory signals, entirely independent of how much iron is actually stored.

That duality creates a diagnostic trap. A ferritin of 120 µg/L returned as "within normal limits" may represent adequate iron stores in an otherwise healthy person — or it may represent near-depleted stores in someone with chronic low-grade inflammation, whose ferritin has been artificially inflated by cytokine signals rather than by iron. Without concurrent context, including a CRP or hs-CRP result, the number alone cannot be decoded.

This article examines what ferritin actually is at a biochemical level, what the Australian reference ranges mean and where they fall short, the evidence behind functional optimal targets, how to interpret both low and high ferritin correctly, and the emerging evidence linking elevated ferritin to cardiometabolic risk through mechanisms entirely distinct from iron overload.

What Ferritin Is: The Iron-Apoferritin Shell Complex

Ferritin is a hollow protein shell — apoferritin — composed of 24 subunits arranged into a cage-like structure roughly 12 nanometres in diameter. Inside that cage, the protein can sequester up to 4,500 iron atoms as ferric oxyhydroxide, holding iron in a soluble, non-toxic, and bioavailable form.

The biology behind this storage mechanism matters for interpretation:

Intracellular function: Ferritin's primary role is intracellular. Inside liver cells, macrophages, and bone marrow cells, ferritin sequesters excess iron and releases it on demand via regulated degradation (ferritinophagy). This protects cells from the oxidative damage that free iron would otherwise cause.
Serum ferritin: A small fraction of intracellular ferritin is secreted into the bloodstream. This serum ferritin fraction is largely iron-poor compared with the intracellular form, but its concentration in circulation closely tracks the size of the body's intracellular iron stores — which is why it is used as a surrogate measure of total body iron.
The storage signal: When iron stores are high, ferritin synthesis is upregulated via iron-responsive elements (IREs) on the ferritin mRNA. When stores fall, ferritin synthesis is suppressed. This makes serum ferritin a reliable proxy for iron status under normal physiological conditions — but not under inflammatory conditions, where a second set of regulatory signals overrides the iron-sensing mechanism.

In short, ferritin is normally an iron sensor. Under inflammation, it becomes an inflammation sensor. The same number can mean very different things depending on the inflammatory environment in which it was produced.

Australian Reference Ranges: What the Lab Cutoffs Actually Represent

According to ptex.au — the Australasian pathology reference cited by the Australian Government's My Health Record — standard reference ranges for serum ferritin in Australian pathology are:

| Population | Australian Reference Range | |---|---| | Adult men | 30–300 µg/L | | Adult women | 15–200 µg/L |

These ranges represent the central 95th percentile of the tested population. That is a statistical construct, not a clinical one. A ferritin of 30 µg/L in a man, or 15 µg/L in a woman, sits right at the lower boundary of "normal" in the statistical sense — but in physiological terms, it represents near-depletion of iron stores. The body's iron reserves at these levels are marginal at best.

This distinction matters in everyday clinical practice. A woman with a ferritin of 18 µg/L will receive a result marked "within normal limits" on most Australian pathology reports. Yet at that level she is operating with minimal iron reserves — enough to avoid frank anaemia under resting conditions, but insufficient to support the many non-haematopoietic functions that depend on iron: thyroid peroxidase activity, dopaminergic neurotransmission, mitochondrial electron transport, and hair follicle cycling.

The reference range tells you where the statistical boundary of the tested population falls. It does not tell you where optimal function begins.

Functional Optimal Targets: What the Evidence Supports

Functional medicine practitioners and a growing number of haematologists and GPs use a narrower and higher target range for ferritin that reflects the research on symptom thresholds rather than population statistics.

| Population | Functional Optimal Ferritin | |---|---| | Women of reproductive age | 50–100 µg/L | | Men | 70–150 µg/L | | Postmenopausal women | 70–150 µg/L |

For women of reproductive age, the 50–100 µg/L range emerges consistently in the literature on iron-related symptoms. Hair loss (telogen effluvium) studies have found that ferritin below 40–50 µg/L is associated with increased hair shedding, and that hair regrowth improves when ferritin rises above 70 µg/L. Thyroid function research identifies ferritin below 50 µg/L as a factor impairing T4-to-T3 conversion via reduced thyroid peroxidase activity. Fatigue and cognitive impairment research similarly shows symptom thresholds in the 30–50 µg/L range — well above the laboratory lower bound of 15 µg/L.

For men, the 70–150 µg/L range is supported by data on energy metabolism, cognitive function, and exercise recovery. The higher lower bound reflects both the higher absolute iron stores men typically carry and the lower baseline inflammatory background that makes ferritin a more reliable iron signal in men than in cycling or pregnant women.

The contrast between the functional optimal floor (50 µg/L for women) and the laboratory lower bound (15 µg/L for women) represents the most commonly missed clinical gap in Australian primary care: tissue iron depletion that causes real, measurable symptoms but produces a result reported as normal.

The Dual Nature Problem: Ferritin as an Acute-Phase Reactant

Understanding ferritin's inflammatory behaviour is the single most important concept in interpreting any ferritin result.

When the immune system is activated — by infection, autoimmune disease, metabolic inflammation, or tissue injury — the liver mounts an acute-phase response. Hepatocytes ramp up synthesis of several proteins, including CRP, fibrinogen, and ferritin. The upstream signals driving this response are primarily interleukin-6 (IL-6) and, to a lesser extent, interleukin-1 (IL-1) and tumour necrosis factor-alpha (TNF-α).

The acute-phase upregulation of ferritin is independent of iron status. The liver does not produce more ferritin because there is more iron to store — it produces more ferritin because the inflammatory milieu instructs it to. The biological rationale is partly protective: sequestering iron into ferritin reduces the free iron available to iron-dependent pathogens, a phenomenon known as "nutritional immunity."

The clinical consequence is that inflammation inflates ferritin artificially. A person with chronic low-grade inflammation — metabolic syndrome, non-alcoholic fatty liver disease (NAFLD), chronic low-level infection, or even obesity — may carry a ferritin in the 100–200 µg/L range that looks reassuring but conceals genuinely depleted iron stores. Their actual tissue iron status may be poor; the ferritin number is elevated by IL-6 production rather than by iron.

The practical rule: Ferritin cannot be interpreted accurately without concurrent CRP. Specifically:

If ferritin is elevated and CRP is also elevated (>5 mg/L on standard CRP, or >1 mg/L on hs-CRP), the ferritin elevation may reflect inflammation rather than iron overload. Retest once the inflammatory trigger resolves.
If ferritin appears normal but CRP is elevated, the true iron stores may be lower than ferritin suggests. Consider transferrin saturation and soluble transferrin receptor to clarify.
If ferritin is elevated and CRP is normal, the elevated ferritin warrants investigation for genuine iron overload — particularly haemochromatosis.

For a full treatment of CRP interpretation and inflammatory risk assessment, see CRP and hs-CRP optimal levels.

Low Ferritin: Iron Deficiency Before Anaemia

The most important clinical concept in ferritin interpretation is that iron depletion causes symptoms long before haemoglobin falls. This state — iron deficiency without anaemia, sometimes called non-anaemic iron deficiency or tissue iron depletion — is the most prevalent and most under-treated iron disorder in Australian practice.

Why Symptoms Precede Anaemia

The bone marrow preferentially directs available iron toward haemoglobin synthesis. As stores decline, erythropoiesis is maintained at the expense of other iron-dependent processes: myoglobin in muscle tissue, cytochrome c and iron-sulphur clusters in mitochondria, dopamine synthesis enzymes in the brain, thyroid peroxidase in the thyroid. By the time haemoglobin falls, the body has already been operating with compromised cellular iron metabolism for months.

This produces a recognisable symptom cluster at ferritin levels well above the anaemia threshold:

Persistent fatigue and reduced exercise tolerance
Cognitive impairment — brain fog, poor concentration, word-finding difficulty
Hair loss (telogen effluvium — diffuse shedding typically beginning 6–12 weeks after stores fall)
Restless legs syndrome (iron is required for dopamine synthesis in the striatum)
Cold intolerance — impaired peripheral thermogenesis
Reduced immune function

All of these can present when ferritin is 20–45 µg/L — technically "within range" by most laboratory standards, and with a completely normal haemoglobin.

Treatment Options

Dietary iron: Haem iron from red meat provides 20–30% absorption; non-haem iron from legumes, seeds, and leafy greens provides 2–10%. Consuming vitamin C alongside non-haem sources doubles absorption by reducing ferric (Fe³⁺) to the absorbable ferrous (Fe²⁺) form.

Oral supplementation — ferrous vs ferric vs bisglycinate: Ferrous sulfate (the most commonly prescribed form in Australia) provides approximately 65 mg of elemental iron per 200 mg tablet and is effective but frequently causes GI side effects — constipation, nausea, and dark stools. Ferrous gluconate and ferrous fumarate are alternative ferrous salts with marginally better tolerability profiles. Ferric forms (ferric carboxymaltose is the IV preparation; ferric polymaltose is used orally) are less well absorbed in oral formulations compared with ferrous forms. Ferrous bisglycinate (chelated iron) provides lower elemental iron doses but superior mucosal uptake efficiency — the glycinate chelation protects iron from dietary inhibitors and improves absorption across the enterocyte membrane — with substantially better tolerability than iron salts. Alternate-day dosing is supported by research from the Lancet Haematology (Stoffel et al., 2017) showing that daily dosing triggers hepcidin upregulation that suppresses next-day absorption; every-other-day dosing improves overall iron absorbed per dose.

Intravenous iron: Available via GP or specialist referral for severe deficiency (ferritin below 15 µg/L with symptoms), failed oral supplementation, malabsorption syndromes, or rapid repletion requirements. IV iron bypasses GI absorption entirely and can raise ferritin by 100–200 µg/L in a single infusion.

For a comprehensive breakdown of the full iron panel and all supplementation protocols, see the iron panel complete guide.

High Ferritin: The Two-Step Interpretation Protocol

An elevated ferritin result — particularly above 200–300 µg/L — should never be accepted at face value. The first question is always whether the elevation reflects genuine iron excess or inflammatory upregulation.

Step 1: Check CRP

Concurrent CRP is essential. If CRP is elevated alongside ferritin, inflammation is likely driving at least part of the ferritin elevation. Identify and address the inflammatory source — infection, autoimmune disease, NAFLD, metabolic syndrome, alcohol use — before interpreting ferritin as an indicator of iron overload.

Common causes of inflammation-driven high ferritin:

Metabolic syndrome and obesity: Visceral adipose tissue secretes IL-6 continuously, chronically elevating both CRP and ferritin. Ferritin in the 150–400 µg/L range is common in people with central obesity and insulin resistance, even without any iron overload.
Non-alcoholic fatty liver disease (NAFLD/MASLD): Hepatic inflammation from lipid accumulation drives ferritin elevation via both acute-phase signalling and direct hepatocellular release of stored ferritin. GGT and ALT/AST provide complementary information — see the ALT and AST liver enzyme guide.
Alcohol excess: Alcohol elevates ferritin through liver inflammation, impaired ferritin clearance, and direct hepatotoxicity. Ferritin of 200–600 µg/L in someone with significant alcohol intake is common and reflects liver status rather than iron overload.
Chronic infection and autoimmune disease: Any persistently activated immune state will upregulate ferritin via IL-6.

Step 2: Assess Transferrin Saturation

If CRP is normal and ferritin remains elevated, the next step is transferrin saturation (TSAT) on a fasting morning sample. A TSAT above 45% on a fasted sample is the primary screening marker for hereditary haemochromatosis and warrants HFE gene testing.

Haemochromatosis: The Iron Overload Diagnosis Most Commonly Missed

Hereditary haemochromatosis (HH) is one of the most prevalent single-gene disorders in Australia. The HFE gene on chromosome 6 encodes a protein that regulates hepcidin — the hepatic hormone that governs intestinal iron absorption. When HFE is mutated, hepcidin production is inappropriately low, and the intestine continues absorbing iron regardless of body stores. Over years to decades, iron accumulates in parenchymal organs.

Prevalence in the Australian population: Approximately 1 in 200 Australians of Northern European (particularly Irish, Scottish, and Scandinavian) descent carries two copies of the C282Y mutation — the primary pathogenic variant — making homozygous HFE haemochromatosis highly prevalent in the Australian context. The compound heterozygous state (one copy of C282Y and one copy of H63D) is also clinically significant and similarly prevalent.

The screening protocol:

| Marker | Haemochromatosis Signal | |---|---| | Transferrin saturation (fasting) | >45% — primary screening threshold | | Ferritin | Elevated, often >300 µg/L in women, >400 µg/L in men at presentation | | CRP | Normal — distinguishes from inflammation-driven ferritin elevation | | HFE gene testing | C282Y and H63D mutation analysis — Medicare-rebatable with elevated TSAT |

The critical point: fasting transferrin saturation rises before ferritin becomes dramatically elevated. Ferritin can appear within or near the reference range in early-stage haemochromatosis while TSAT is already above 50%. This is why TSAT, not ferritin, is the most sensitive early screen.

Treatment: Regular therapeutic venesection (phlebotomy) — removing 450–500 mL of blood every 1–2 weeks during the depletion phase, then maintenance every 2–4 months — is definitive, simple, safe, and inexpensive. When initiated before significant organ iron deposition, life expectancy is normal. Untreated, progressive iron accumulation leads to liver cirrhosis, hepatocellular carcinoma, cardiomyopathy, diabetes, hypogonadism, and arthropathy.

Ferritin and Cardiometabolic Risk: The Fenton Reaction Connection

Beyond haemochromatosis, there is an independent and under-recognised connection between elevated ferritin and cardiometabolic disease in people without clinical iron overload. The mechanism is oxidative stress mediated by free iron.

The Fenton reaction describes the chemistry at the core of iron-catalysed oxidative damage: ferrous iron (Fe²⁺) reacts with hydrogen peroxide to produce hydroxyl radical (•OH) — one of the most reactive and destructive oxidising species in biology. Hydroxyl radical attacks lipid membranes, oxidises LDL particles (producing atherogenic oxLDL), damages mitochondrial DNA, and induces hepatocellular injury.

When iron stores are elevated above the physiological optimum — even in the sub-haemochromatosis range — the risk of this Fenton chemistry increases, particularly in the context of metabolic disease where hydrogen peroxide production from dysfunctional mitochondria is already elevated.

The epidemiological picture is consistent with this mechanism:

Elevated ferritin (in the range of 200–400 µg/L, independent of CRP) is associated in prospective studies with increased risk of type 2 diabetes, metabolic syndrome, and NAFLD — after adjustment for inflammatory markers.
Observational data from large cohorts link ferritin in the upper-normal range to insulin resistance via mechanisms consistent with hepatic iron-mediated oxidative stress impairing insulin signalling.
The association between elevated ferritin and uric acid is noteworthy — uric acid functions partly as an antioxidant scavenging free iron, and its elevation in metabolic syndrome may reflect a compensatory response to iron-driven oxidative stress. The connection between uric acid and metabolic health is explored in uric acid as a metabolic marker.

This cardiometabolic connection reinforces the value of keeping ferritin within the functional optimal range rather than simply below the laboratory upper bound. For most adults, ferritin progressively drifting toward 250–400 µg/L without a clear inflammatory trigger warrants investigation and consideration of dietary iron reduction, increased blood donation, and monitoring of transferrin saturation.

Ferritin in Context: Building the Full Picture

Ferritin is most accurately interpreted as one component of an integrated panel. The key companion markers:

| Companion Marker | Why It Matters | |---|---| | CRP / hs-CRP | Distinguishes iron overload from inflammation-driven ferritin elevation | | Transferrin saturation (fasting) | Required for haemochromatosis screening; detects iron overload earlier than ferritin | | Serum iron and TIBC | Triangulates iron supply and transport capacity | | ALT and AST | Elevated with NAFLD and alcohol — both common causes of high ferritin | | HbA1c and fasting insulin | Metabolic syndrome drives ferritin elevation independently of iron | | Soluble transferrin receptor (sTfR) | Unaffected by inflammation — rises in true iron deficiency even when ferritin is normal |

For comprehensive iron panel interpretation including every marker and diagnostic pattern, see the iron panel complete guide. For the liver enzyme picture, see ALT and AST liver enzyme interpretation.

Those following research into peptides and metabolic health — including the intersection of iron metabolism, mitochondrial function, and oxidative stress — can find a summary of the current evidence base at RetaLABS research.

Key Takeaways

Ferritin is an iron-storage protein (apoferritin shell complex) whose serum concentration reflects total body iron stores under normal conditions — but is upregulated by IL-6 and other inflammatory signals independently of iron status.
Australian reference ranges (men 30–300 µg/L, women 15–200 µg/L, per ptex.au — the Australasian pathology reference linked from the Australian Government My Health Record) represent statistical population cutoffs, not functional sufficiency thresholds.
Functional optimal targets are 50–100 µg/L for women of reproductive age and 70–150 µg/L for men — derived from symptom threshold research rather than population statistics.
Low ferritin causes fatigue, hair loss, brain fog, restless legs, and cold intolerance at levels above the anaemia threshold — the pre-anaemic iron deficiency pattern is the most commonly missed finding in Australian primary care.
High ferritin must be interpreted with concurrent CRP. Elevated ferritin with elevated CRP suggests inflammation is the driver. Elevated ferritin with normal CRP warrants transferrin saturation testing to screen for haemochromatosis.
Haemochromatosis (HFE C282Y homozygosity) affects approximately 1 in 200 Australians of Northern European descent. Fasting transferrin saturation above 45% is the primary screening signal — it rises before ferritin becomes dramatically elevated.
Elevated ferritin in the absence of inflammation is associated with insulin resistance, NAFLD, and metabolic syndrome through iron-catalysed oxidative stress via the Fenton reaction.

This article is for educational purposes only and does not constitute medical advice. Reference ranges vary between Australian pathology laboratories. Consult a qualified medical practitioner for interpretation of your individual results, before commencing iron supplementation, and before investigation for haemochromatosis.